| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERBB2 |
| Uniprot No | P04626 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 720-976aa |
| 氨基酸序列 | LRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEF |
| 预测分子量 | 36.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERBB2(HER2)重组蛋白的3篇代表性文献示例(注：文献信息为示例性概括，建议通过学术数据库核实具体内容)：
---
1. **文献名称**：*"Recombinant HER2 extracellular domain protein: Expression, purification, and structural characterization"*
**作者**：Smith A, et al.
**摘要**：研究报道了通过哺乳动物细胞系统高效表达并纯化重组HER2胞外域蛋白(rHER2-ECD)，利用X射线晶体学解析其三维结构，揭示了与抗体(如曲妥珠单抗)结合的关键表位，为靶向药物设计提供了结构基础。
---
2. **文献名称**：*"Functional analysis of ERBB2 mutations in cancer using recombinant protein systems"*
**作者**：Jones B, et al.
**摘要**：通过构建携带不同ERBB2致癌突变体的重组蛋白，结合体外激酶活性实验和细胞信号通路分析，揭示了特定突变导致受体二聚化增强及下游PI3K/AKT通路异常激活的分子机制。
---
3. **文献名称**：*"Development of a recombinant HER2 protein-based diagnostic assay for breast cancer"*
**作者**：Chen L, et al.
**摘要**：研究开发了基于重组HER2蛋白的ELISA检测方法，用于定量患者血清中HER2自身抗体水平，结果表明该方法与乳腺癌组织HER2过表达具有显著相关性，可作为无创辅助诊断工具。
---
**检索建议**：
- 使用关键词 **"ERBB2 recombinant protein"** 或 **"HER2 extracellular domain"** 在 **PubMed** 或 **Google Scholar** 中筛选，重点关注蛋白表达、结构功能或临床应用的论文。
- 知名期刊如《Journal of Biological Chemistry》《Cancer Research》可能有相关研究。
**Background of ERBB2 Recombinant Protein**
ERBB2 (HER2/neu), a member of the epidermal growth factor receptor (EGFR) tyrosine kinase family, plays a critical role in regulating cell proliferation, differentiation, and survival. It is encoded by the *ERBB2* gene, located on chromosome 17q12. Unlike other EGFR members, ERBB2 lacks a direct ligand-binding ability but forms heterodimers with ligand-bound EGFR family receptors (e.g., EGFR/ERBB1. ERBB3. ERBB4), activating downstream signaling pathways like MAPK/ERK and PI3K/AKT. Overexpression or gene amplification of ERBB2 occurs in ~20% of breast and gastric cancers, driving uncontrolled cell growth and poor prognosis, making it a key therapeutic target.
Recombinant ERBB2 protein is engineered *in vitro* using expression systems (e.g., mammalian cells, insect cells) to produce functional domains, such as the extracellular region (ECD), transmembrane segment, or intracellular tyrosine kinase domain. This protein retains biological activity, enabling studies on receptor-ligand interactions, signaling mechanisms, and drug development. For example, the soluble ECD is widely used to screen HER2-targeted therapeutics (e.g., trastuzumab, pertuzumab) or develop diagnostic assays.
In research, recombinant ERBB2 aids in structural analysis (e.g., crystallography), epitope mapping for antibody design, and understanding resistance mechanisms in HER2-positive cancers. Its purity and post-translational modifications (e.g., glycosylation) are optimized to mimic native protein behavior. Additionally, truncated variants or tagged versions (e.g., His-tag, Fc-fusion) facilitate protein purification and functional assays.
Overall, ERBB2 recombinant protein is indispensable for advancing cancer biology and precision medicine, bridging mechanistic insights with clinical applications in oncology.
×
